The China’s State Food and Drug Administration has granted approval to Sihuan Pharmaceutical to initiate a clinical study of pinoxacin hydrochloride to treat patients with type II diabetes.

Pinoxacin hydrochloride, a category 1.1 drug, is a DPP-4 inhibitor class of oral hypoglycemic agents used to enhance the function of endogenous insulin, improving glycemic control and islet beta-cells function.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

During the company’s pre-clinical research, DPP-4 inhibitors have shown potent in-vitro and in-vivo activities, good selection profile, great stability and controllable quality, as well as better tolerance, with long-term administration showing a protective effect on pancreatic beta-cells.

"Pinoxacin hydrochloride is a DPP-4 inhibitor class of oral hypoglycemic agents used to enhance the function of endogenous insulin, improving glycemic control and islet beta-cells function."

The company’s research also showed that DPP-4 inhibitors will not cause serious side effects such as weight gain and hypoglycaemia when compared to conventional diabetes drugs.

Pinoxacin hydrochloride has good pharmacokinetic characteristics, high oral bioavailability, quick absorption, rapid onset and a longer duration, claims the company.

See Also:

The company expects the Phase I clinical study to begin in the first half of 2013.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Sihuan Pharmaceutical chairman and CEO Dr Che Fengsheng said the company believes that after the launch, pinoxacin Hhdrochloride will provide physicians and patients with better treatment options.

"Further to obtaining clinical approval for Benapenum, a class of new drug, in January, the company has again successfully obtained clinical approval for another new drug," Fengsheng said.

"This will enable the company to further consolidate its diversified product lines while driving its sustainable growth."